REGN - REGENERON PHARMACEUTICALS, INC.

610.86
8.220   1.346%

Share volume: 1,173,044
Last Updated: 04-28-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.10%

PREVIOUS CLOSE
CHG
CHG%
$602.64
8.22
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
69%
Profitability 63%
Dept financing 38%
Liquidity 75%
Performance 81%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
1.85%
1 Month
-3.68%
3 Months
-11.12%
6 Months
-34.13%
1 Year
-31.55%
2 Year
-24.28%
Key data
Stock price
$610.86
P/E Ratio 
17.74
DAY RANGE
$601.19 - $614.83
EPS 
$37.77
52 WEEK RANGE
$525.99 - $1,211.20
52 WEEK CHANGE
-$31.41
MARKET CAP 
78.278 B
YIELD 
N/A
SHARES OUTSTANDING 
108.417 M
DIVIDEND
$0.88
EX-DIVIDEND DATE
02-20-2025
NEXT EARNINGS DATE
04-29-2025
BETA 
0.60
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$1,004,858
AVERAGE 30 VOLUME 
$1,119,491
Company detail
CEO: Leonard S. Schleifer
Region: US
Website: regeneron.com
Employees: 11,900
IPO year: 1991
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema. Dupixent injection is used to treat atopic dermatitis and asthma in adults and pediatrics. Kevzara solution for treating rheumatoid arthritis in adults.

Recent news
loading